Nasdaq

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to ...

SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves ...
Seeking Alpha

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc (SPRY). (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...
MedPage Today

FDA Panel Backs Needle-Free Epinephrine for Anaphylaxis

FDA advisors recommended that the agency approve an intranasal epinephrine product for type I allergic reactions, including anaphylaxis, despite concerns about the lack of clinical efficacy data. On ...
Nasdaq

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect ARS Pharmaceuticals has also submitted a supplemental New Drug Application ...